1. Expression of Calcitonin Gene-Related Peptide and Calcitonin Receptor-like Receptor in Colorectal Adenocarcinoma.
- Author
-
Șerban RE, Stepan MD, Florescu DN, Boldeanu MV, Florescu MM, Șerbănescu MS, Ionescu M, Streba L, Drăgoescu NA, Christopher P, Obleagă VC, Constantin C, and Vere CC
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Neoplasm Staging, Adult, Aged, 80 and over, Prognosis, Gene Expression Regulation, Neoplastic, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Colorectal Neoplasms blood, Calcitonin Gene-Related Peptide metabolism, Calcitonin Gene-Related Peptide blood, Calcitonin Receptor-Like Protein metabolism, Calcitonin Receptor-Like Protein genetics, Adenocarcinoma metabolism, Adenocarcinoma pathology, Adenocarcinoma blood, Biomarkers, Tumor blood, Biomarkers, Tumor metabolism
- Abstract
Colorectal cancer is one of the most widespread types of cancer that still causes many deaths worldwide. The development of new diagnostic and prognostic markers, as well as new therapeutic methods, is necessary. The calcitonin gene-related peptide (CGRP) neuropeptide alongside its receptor calcitonin receptor-like receptor (CRLR) could represent future biomarkers and a potential therapeutic target. Increased levels of CGRP have been demonstrated in thyroid, prostate, lung, and breast cancers and may also have a role in colorectal cancer. At the tumor level, it acts through different mechanisms, such as the angiogenesis, migration, and proliferation of tumor cells. The aim of this study was to measure the level of CGRP in colorectal cancer patients' serum by enzyme-linked immunosorbent assay (ELISA) and determine the level of CGRP and CRLR at the tumor level after histopathological (HP) and immunohistochemical (IHC) analysis, and then to correlate them with the TNM stage and with different tumoral characteristics. A total of 54 patients with newly diagnosed colorectal adenocarcinoma were evaluated. We showed that serum levels of CGRP, as well as CGRP and CRLR tumor level expression, correlate with the TNM stage, with local tumor extension, the presence of lymph node metastasis, and distant metastasis, and also with the tumor differentiation degree. CGRP is present in colorectal cancer from the incipient TNM stage, with levels increasing with the stage, and can be used as a diagnostic and prognostic marker and may also represent a potentially new therapeutic target.
- Published
- 2024
- Full Text
- View/download PDF